phathompharma.com (PHAT): רווח נקי למניה ב-12 החודשים האחרונים
Phathom Pharmaceuticals (PHAT) has achieved financial stability driven by the success of its erosive esophagitis therapy. The rolling 12-month earnings per share trend captures this progress, with the metric currently standing at -1.04. Growth is supported by strategic alliances with retail chains, although pressure from generics and new patents from industry behemoths creates certain risks for the issuer's market share.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PHAT_-_Phathom-Pharmaceuticals_-_Earnings-per-share-for-the-last-four-quarters "Phathom Pharma - רווח למניה בשנים עשר החודשים האחרונים PHAT (תקופה 04.07.2022 - 14.11.2026) | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור Phathom Pharma (PHAT)
Assessing the financial stability of Phathom Pharmaceuticals (PHAT) requires an analysis of real returns adjusted for the impact of issuance changes. This metric measures the final annual earnings per share, which, combined with the net income per share over the last four quarters, allows for an evaluation of the R&D model's efficiency and the dependence of margins on the reliability of contract drug manufacturers.
